Literature DB >> 10368126

Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice.

L E Rohde1, A Ducharme, L H Arroyo, M Aikawa, G H Sukhova, A Lopez-Anaya, K F McClure, P G Mitchell, P Libby, R T Lee.   

Abstract

BACKGROUND: Extracellular matrix synthesis and degradation contribute to the morphological changes that occur after myocardial infarction (MI). METHODS AND
RESULTS: We tested the hypothesis that inhibition of matrix metalloproteinases (MMPs) attenuates left ventricular remodeling in experimental MI. Seventy-one male FVB mice that survived ligation of the left anterior coronary artery were randomized to a broad-spectrum MMP inhibitor (CP-471,474) or placebo by gavage. Echocardiographic studies were performed before randomization (within 24 hours of surgery) and 4 days later and included short-axis imaging at the midpapillary and apical levels. Infarction as defined by wall motion abnormality was achieved in 79% of the procedures (n=56), and mortality rate during the 4-day protocol was 23% (9 of 36 on treatment vs 7 of 35 on placebo; P=NS). Baseline end-diastolic and end-systolic dimensions and areas were similar (P=NS) between treated and placebo groups. At follow-up, infarcted mice allocated to MMP inhibitor had significantly smaller increases in end-systolic and end-diastolic dimensions and areas at both midpapillary and apical levels compared with infarcted mice allocated to placebo (all P<0.05). In addition, infarcted animals that received MMP inhibitor had no change in fractional shortening (-3+/-13%), whereas animals that received placebo had a decrease in fractional shortening (-12+/-12%) (P<0.05). In an analysis stratified by baseline end-diastolic area, the effects of MMP inhibition on the changes in end-systolic area and end-diastolic area were most prominent in animals that had more initial left ventricular dilatation (both P<0.05).
CONCLUSIONS: -Administration of an MMP inhibitor attenuates early left ventricular dilation after experimental MI in mice. Further studies in genetically altered mice and other models will improve understanding of the role of MMPs in left ventricular remodeling.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10368126     DOI: 10.1161/01.cir.99.23.3063

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  105 in total

1.  Proteinases in cardiovascular aneurysms and rupture: targets for therapy?

Authors:  P Carmeliet
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

2.  Matrix metalloproteinases: not-so-innocent bystanders in heart failure.

Authors:  R T Lee; P Libby
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

3.  Anisotropic reinforcement of acute anteroapical infarcts improves pump function.

Authors:  Gregory M Fomovsky; Samantha A Clark; Katherine M Parker; Gorav Ailawadi; Jeffrey W Holmes
Journal:  Circ Heart Fail       Date:  2012-06-04       Impact factor: 8.790

4.  Effects of telmisartan on markers of ventricular remodeling in patients with acute myocardial infarction: comparison with enalapril.

Authors:  Takashi Yokota; Tomohiro Osanai; Kenji Hanada; Motoi Kushibiki; Naoki Abe; Koichi Oikawa; Hirofumi Tomita; Takumi Higuma; Jin Yokoyama; Hiroyuki Hanada; Ken Okumura
Journal:  Heart Vessels       Date:  2010-10-05       Impact factor: 2.037

5.  Spatiotemporal induction of matrix metalloproteinase-9 transcription after discrete myocardial injury.

Authors:  Rupak Mukherjee; Gregory P Colbath; Charles D Justus; James A Bruce; Claire M Allen; Kenneth W Hewett; J Philip Saul; Robert G Gourdie; Francis G Spinale
Journal:  FASEB J       Date:  2010-06-08       Impact factor: 5.191

6.  Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction.

Authors:  Ellen O Weinberg; Masahisa Shimpo; Gilles W De Keulenaer; Catherine MacGillivray; Shin-ichi Tominaga; Scott D Solomon; Jean-Lucien Rouleau; Richard T Lee
Journal:  Circulation       Date:  2002-12-03       Impact factor: 29.690

Review 7.  The dynamic interaction between matrix metalloproteinase activity and adverse myocardial remodeling.

Authors:  Joseph S Janicki; Gregory L Brower; Jason D Gardner; Amanda L Chancey; James A Stewart
Journal:  Heart Fail Rev       Date:  2004-01       Impact factor: 4.214

8.  Helix-loop-helix protein p8, a transcriptional regulator required for cardiomyocyte hypertrophy and cardiac fibroblast matrix metalloprotease induction.

Authors:  Sandro Goruppi; Richard D Patten; Thomas Force; John M Kyriakis
Journal:  Mol Cell Biol       Date:  2006-11-20       Impact factor: 4.272

9.  Nicorandil suppresses the increases in plasma level of matrix metalloproteinase activity and attenuates left ventricular remodeling in patients with acute myocardial infarction.

Authors:  Takayuki Fujiwara; Toshiro Matsunaga; Kunihiko Kameda; Naoki Abe; Hirotsugu Ono; Takumi Higuma; Jin Yokoyama; Hiroyuki Hanada; Tomohiro Osanai; Ken Okumura
Journal:  Heart Vessels       Date:  2007-09-20       Impact factor: 2.037

10.  Advances in radionuclide molecular imaging in myocardial biology.

Authors:  Alan R Morrison; Albert J Sinusas
Journal:  J Nucl Cardiol       Date:  2010 Jan-Feb       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.